Analyst Research

Report Title Price
Thomson Reuters Stock Report - OCLARO, INCORPORATION (OCLR-O)
Provider: Thomson Reuters Stock Report
$25.00
Buy
Oclaro, Inc. (OCLR) - Medical Equipment - Deals and Alliances Profile
Provider: GlobalData
$250.00
Buy
OCLARO INC (OCLR) Zacks Company Snapshot
Provider: Zacks Investment Research Inc.
$12.00
Buy
OCLARO INC (OCLR) Zacks Company Snapshot
Provider: Zacks Investment Research Inc.
$12.00
Buy

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

» More Analyst Research

Oclaro Inc Issues Q3 2013 Guidance Below Analysts' Estimates


Thursday, 31 Jan 2013 04:10pm EST 

Oclaro Inc announced that for the third quarter of 2013, it expects revenues in the range of $140 million to $155 million and adjusted EBITDA in the range of negative $25 million to negative $13.5 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $156 million and EBITDA of $(9.2) million for third quarter of 2013. 

Latest Developments for Oclaro Inc

Latest Key Developments in Medical

Company Quote

Oclaro Inc
(OCLR.OQ)
1.09
0.0 +0.00%
23 May 2013